NewcelX (NCEL) Stock Price

NewcelX Price

CLOSED
2.50
​
Market closed

NewcelX stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NewcelX business model & stock analysis

NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company is headquartered in Zurich, Zuerich and currently employs 2 full-time employees. The company went IPO on 2021-01-29. The firm focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The firm serves customers worldwide.

Frequently asked questions about NewcelX

7 analysts currently rate the NewcelX stock: 6 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the NewcelX share trades at 2.22 EUR (2.50 USD).

The revenue cannot currently be calculated for NewcelX.

The expected profit of NewcelX is -5.38 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of NewcelX is currently -2.23. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the NewcelX stock.

The P/S cannot be calculated for NewcelX currently.

The Eulerpool Quality Score for NewcelX is 2/10.

The ISIN of NewcelX is CH1442297896. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of NewcelX is NCEL. The ticker symbol is used to trade NewcelX shares on the stock exchange.

Fair ValueTerminal
2.28 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Jan 29, 2021
ISIN
CH1442297896
Cusip
H57830103
Market capitalization
11.40 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-2.23
P/Ee 2027
-4.38
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
1.57
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-109.14 %
Last updated Oct 17, 2026, 6:31 PM

NewcelX Peer Group

All fundamentals and in-depth analysis of NewcelX

Our stock analysis for NewcelX stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of NewcelX. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.